Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke’s encephalopathy
Sign Up to like & getrecommendations! Published in 2017 at "Neuroscience Letters"
DOI: 10.1016/j.neulet.2017.01.041
Abstract: Recent clinical trials suggest that patients with myelofibrosis can develop Wernicke's encephalopathy (WE) when treated with fedratinib, a specific Janus kinase-2 (JAK-2) inhibitor. To investigate this issue, we have examined (1) if fedratinib can produce… read more here.
Keywords: inhibitor; jak inhibitor; treatment; fedratinib lead ... See more keywords